P/B
3,1
GT Biopharma
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.
$11M
Market Cap • 10/2/2026
1973
(53 years)
Founded
2021
(5 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
—
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
0,1
BVPS
2
EPS
—
Market Cap
Market Cap
11M
EV
6M
EV/Revenue
0
EV/EBITDA
-0,4
EV/EBIT
-0,4
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-55,2%
Total Yield
-55,2%
Payout
0%
Retained Earnings
-731,4M
Profitability
Gross Margin
—
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
0%
Capex/Revenue
0%
Capex/D&A
0%
Capex/OCF
0%
SBC/OCF
—
% PPE
0%
% Goodwill
0%
ROE
46,8%
ROIC
—
Growth
CAGR Net Income 5Y
-35,8%
CAGR OCF 5Y
4,5%
Leverage
N.D./EBITDA
0,3
Debt/Equity
0%
Current Ratio
2,5
Quick Ratio
2,2
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!